Study drugs for blood-vessel Behçet’s to reduce inflammation
Treatments studied
Part of Eyes & vision, Genetic & congenital, Heart & circulation, Mouth & dental, Skin clinical trials.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign the consent form before any study procedures.
- You’re 18 to 65 years old.
- You meet established criteria for Behçet’s disease.
- Your aorta and/or leg/arm arteries have an aneurysm or bulging area confirmed by ultrasound or CT angiography.
- Your blood tests show high inflammation markers (ESR and hs-CRP).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests infliximab, a medicine that calms inflammation, for dolichoectactic aneurysms in the vertebral/basilar brain blood vessels that usually cannot be treated with standard surgery or procedures. The goal is to see if it can improve safety and how the aneurysm behaves over time.
This study tests a medication called corticotropin (a hormone that may help control inflammation) to see if it can reduce symptoms of Behçet's disease, especially painful mouth ulcers. If you have active ulcers, this treatment might help you get relief.
This study tests a new pill called Hemay005 for adults with Behçet's disease who have at least two mouth sores that need treatment beyond creams or rinses. It aims to see if the drug safely reduces mouth ulcers.
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
This trial studies lenalidomide to treat frequent, ongoing mouth ulcers caused by mucosal Behçet’s syndrome. It’s meant for people whose mouth sores keep coming back despite standard treatments like steroid medicines and other immune-suppressing drugs.
This study tests whether adding a blood thinner (rivaroxaban) to standard immune therapy is better than immune therapy alone for treating blood clots in the legs caused by Behçet's disease. It may help prevent clots from getting worse or recurring.
Hear when a new Aneurysm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.